Key data highlights from SPL026 Phase IIa trial – Dr. Carol Routledge

Our Chief Medical & Scientific Officer Dr Carol Routledge, discusses some of the key result highlights from our Phase IIa trial of SPL026, what these results could mean for a potential future treatment, and what we’ll seek to explore in later-stage clinical trials.

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates

    Corporate Presentation

    Follow us: